


# 2025@Philly

## Cell and Gene Therapy Conference



Philadelphia 费城  
sapagp.org



**27 - 28 June, 2025**

Sheraton Valley Forge Hotel,  
480 N Gulph Rd. King of Prussia,  
PA 19406



# PHILLY

Advanced Cell and Gene Therapy  
in Philadelphia

# SAPA-GP

## Vision

To make lasting impact in the life science community in the Greater Philadelphia area by becoming a go-to organization for professional networking and leadership development bringing key stakeholders together and supporting regional initiatives

## Mission

To promote pharmaceutical sciences and biotechnology  
To contribute to public health education by raising public awareness  
To facilitate scientific and business cooperation  
To foster the career development of pharmaceutical professionals



# Welcome Letter

Dear Esteemed Guests and Colleagues,

Welcome to the @Philly Cell and Gene Therapy Conference 2025! We are excited to host you in the vibrant suburbs of Philadelphia for this pivotal event in the field of cell and gene therapies.

Our mission is to foster knowledge exchange, professional growth, and networking within the thriving Cell and Gene Therapy ecosystem in the Greater Philadelphia area. This year's conference promises to be impactful, featuring expert-led sessions, insightful panel discussions, and invaluable networking opportunities that will propel the field forward. We are honored to welcome a distinguished lineup of speakers, valued sponsors, and passionate attendees—each bringing invaluable insights, support, and energy that will help shape the future of this transformative field.

The past year has seen remarkable progress, with FDA approvals for therapies such as Amtagvi, Beqve, Tecelra, Aucatzyl, Kebilidi, Ryoncil, Symvess, Encelto, and Zevaskyn. In 2024, we achieved record "firsts," including the first approvals for TIL therapy (Amtagvi), TCR therapy (Tecelra), and mesenchymal stem cell product (Ryoncil). 2025 is expected to continue this momentum, with FDA projecting 10–20 CGT approvals annually.

While the industry has faced challenges recently, the Greater Philadelphia area remains a vibrant hub for cell and gene therapy. By supporting one another, we can overcome these trials and ensure the industry's continued growth and success. Together, we can drive innovation and keep this field thriving.

We hope you find this event informative and inspiring. We extend our heartfelt gratitude to the speakers, organizers, sponsors, volunteers, and all who contributed to making this conference possible. Your dedication is deeply appreciated.

Thank you for joining us in Philadelphia. We wish you to have a productive and enjoyable conference.

Sincerely,  
SAPA-GP President Office



Xinjun Zhang, Ph.D.,  
President-elect of SAPA-GP  
2026-2027  
Conference Co-Chair



Lu Wang, Ph.D., M.B.A.,  
President of SAPA-GP  
2025-2026  
Conference Chair



Yufeng Li, Ph.D.,  
Immediate Past President  
of SAPA-GP 2024-2025  
Conference Co-Chair

# Sponsors



# Partnerships



The Chamber of Commerce  
of the Greater Philadelphia



Est. by the Hepatitis B Foundation



HOPE FOR RARE  
FOUNDATION  
瑞鸥公益基金会



# Program-At-A-Glance

Friday June 27<sup>th</sup>

**8:00 a.m.** Registration

**8:40 a.m.** **Opening Remarks** *Grand Ballroom*  
 Lu Wang, Ph.D., M.B.A., President, SAPA-GP 2025-26, Conference Chair, Director, CMC  
 Process Development, Genetech Inc.

**8:50 a.m.** **Keynote Speech: New Business Models for Rare Disease Gene Therapies** *Grand Ballroom*  
 James Wilson, Ph.D., M.D., CEO, GEMMA Biotherapeutics

**9:40 a.m.** **Coffee Break & Networking**

<b>CMC</b> <i>Grand Ballroom</i>	<b>Gene Therapy</b> <i>Centenial Ballroom I</i>	<b>Business Track 1</b> <i>Centenial Ballroom II</i>	<b>Business Track 2</b> <i>Centenial Ballroom III</i>
Tract It Back to the Source: Innovation in Plasmid Development	Paving the Way for Transformative Therapies	Tri-State Bio-Economy: What Makes Our Region Stand Out?	Money in the Bank: Structuring Your Initial Funding to Attract Further Capital

**11:30 a.m.** **Lunch & Networking**

<b>11:45 a.m. Lunch Session – Pharmaron</b> <i>Haverford Room</i>	<b>11:45 a.m. Lunch Session – CellPort Software</b> <i>Malvern Room</i>
--	--

**12:50 p.m.** **Keynote Speech: How to Start and Drive a CAR** *Grand Ballroom*  
 James Riley, Ph.D, Professor of Microbiology, University of Pennsylvania

**1:40 p.m.** **Coffee Break & Networking**

<b>CMC</b> <i>Grand Ballroom</i>	<b>Gene Therapy</b> <i>Centenial Ballroom I</i>	<b>Business Track 1</b> <i>Haverford Room</i>	<b>Business Track 2</b> <i>Centenial Ballroom III</i>	<b>Company Showcase</b> <i>Centenial Ballroom II</i>
Manufacturing Process Development: Challenges and Breakthroughs	Novel Targets and Emerging Indications in Gene Therapy	Expanding Philly’s Talent Pipeline for Life Sciences	Women in Business: the Philly Story	Hopstem Biotechnology; Qiagen; Countable Labs

**3:30 p.m.** **Coffee Break & Networking**

<b>CMC</b> <i>Grand Ballroom</i>	<b>Gene Therapy</b> <i>Centenial Ballroom I</i>	<b>Business Track 1</b> <i>Centenial Ballroom II</i>	<b>Business Track 2</b> <i>Centenial Ballroom III</i>
Quality Control: from Analytics to Regulatory	Unlocking Gene Therapy Potential: Scientific Advances and Tools	Sound Policy: Charting a Course Through Turbulent Waters	How Incubators Reshape the Bio-ecosystem

**5:20 p.m.** **Reception**

**6:00 p.m.** **Fireside Chat & Gala Dinner (ticket only)** *Grand Ballroom*  
**9:00 p.m.**

# Program-At-A-Glance

Saturday June 28<sup>th</sup>

8:00 a.m. Registration

9:00 a.m. **Keynote Speech: The Landscape for Cell Therapy and Gene Therapy – From Drug Development to Patient Access** *Grand Ballroom*  
 Phyllis Arthur, M.B.A., Executive Vice President & Head of Healthcare Policy and Programs, Biotechnology Innovation Organization (BIO)

9:50 a.m. **Coffee Break & Networking**

<b>10:10 a.m.</b>	<b>Cell Therapy</b> <i>Grand Ballroom</i>	<b>RNA Therapy</b> <i>Centennial Ballroom I</i>	<b>Clinical &amp; Regulatory</b> <i>Centennial Ballroom III</i>	<b>Business Track 3</b> <i>Centennial Ballroom II</i>
	Recent Advances in Cell Therapy	Clinical Translation of Nucleic Acid-based Therapy	Latest Regulatory Considerations for Gene Therapy	Honorable Exit: MNC and IPO

11:40 a.m. **Lunch & Networking**

<b>1:00 p.m.</b>	<b>Cell Therapy</b> <i>Grand Ballroom</i>	<b>RNA Therapy</b> <i>Centennial Ballroom I</i>	<b>Clinical &amp; Regulatory</b> <i>Centennial Ballroom III</i>	<b>Business Track 3</b> <i>Centennial Ballroom II</i>
	Optimization of CAR-T Cell Development and Safety Detection	Latest Advances in Nucleic Acid Delivery	Early Clinical Development Challenges of Gene and Cell Therapy	Going Global: Asset Assessment and Strategic Positioning for Deals

2:30 p.m. **Coffee Break & Networking**

<b>2:50 p.m.</b>	<b>Career</b> <i>Grand Ballroom</i>	<b>Business Track 3</b> <i>Centennial Ballroom II</i>	<b>Business Track 4</b> <i>Centennial Ballroom III</i>
	<b>2:50 – 3:50 p.m.</b> Panel Discussion: Career Planning for Young Professionals	AI Impact: Harnessing the Coming Tsunami	Realizing Potential: New Drug Commercialization

4:20 p.m. **Reception**

5:20 p.m.

# Map



# Keynote Sessions

Friday June 27<sup>th</sup>

Opening Remark

Grand Ballroom

8:40-8:50 a.m.

[Lu Wang](#), Ph.D., M.B.A., President, SAPA-GP2025-26, Conference Chair,  
Director, CMC Process Development, Genentech Inc

Keynote

Grand Ballroom

Session Host:

[Lu Wang](#), Ph.D., M.B.A., President, SAPA-GP2025-26, Conference Chair,  
Director, CMC Process Development, Genentech Inc

8:50-9:40 a.m.

**New Business Models for Rare Disease Gene Therapies**

[James Wilson](#), Ph.D., M.D., CEO of GEMMA Biotherapeutics

Keynote

Grand Ballroom

Session Host:

[Patricia Tsao](#), Ph.D., M.D., COO and Scientific Director, CytoEX Inc

12:50-1:40 p.m.

**How to start and drive a CAR**

[James Riley](#), Ph.D., Professor of Microbiology, University of Pennsylvania

Saturday June 28<sup>th</sup>

Keynote

Grand Ballroom

Session Host:

[Haichen Yang](#), M.D., M.B.A, M.A., Conference Advisory Committee Co-chair,  
VP, Clinical Research, Amicus Therapeutics

9:00-9:50 a.m.

**The Landscape for Cell Therapy and Gene Therapy - From Drug  
Development to Patient Access**

[Phyllis Arthur](#), M.B.A., EVP & Head, Healthcare Policy and Programs at  
Biotechnology Innovation Organization (BIO)

# Special Events

Friday June 27<sup>th</sup>

Fireside Chat

Grand Ballroom

Session Hosts

6:00-6:20 p.m.

Jing Yang, Ph.D., CSO and Founder, BaseCure Therapeutics  
Yang Yuan, Ph.D., M.B.A., Associate Director, Jazz Pharmaceuticals  
**Bridging International Collaboration on Rare Diseases Research**  
Kevin Huang, Co-founder & CEO, Hope for Rare Foundation

Saturday June 28<sup>th</sup>

Career Development

Grand Ballroom

Panel Discussion: Career Planning for Young Professionals

Session Moderator:

2:50-3:50 p.m.

Panelists:

Tao Niu, Ph.D., Director, Quantitative Clinical Pharmacology, Sarepta Therapeutics  
Patricia Tsao, Ph.D., M.D., Chief Operating Officer and Scientific Director, CytoEX Inc.  
Michael Kalos, Ph.D., Managing Director, Next Pillar Consulting, LLC  
Dharmesh Patel, Ph.D., MBA, Founder and CEO, Nexis BioConsult  
Xiao Shelley Hu, Ph.D., President and Founder, Translational Consulting L.L.C.  
Bo Liang, Ph.D., Founder and CEO, IVIEW Therapeutics Inc.  
Amanda K. Purdy, Ph.D., Associate Chief Academic Officer of Fox Chase Cancer Center & Co-Chair of Philly Chapter of Women in Bio  
Vibha Jawa, Ph.D., FAAPS, Chief Scientific Officer, EpiVax, Inc.

# Sponsor Sessions

Friday June 27<sup>th</sup> – Lunch Session and Company Showcase

## Pharmaron Lunch Session

Haverford Room

**Session Host:**

11:45 a.m.-12:45 p.m.

[Zhiyi Cui](#), Ph.D., Associate Director, DMPK, GSK

**CGT Potency Assays: Real Challenges, Real Solutions, Real Impacts**

[Silvia Pires Lourenco](#), M.S., Ph.D., Director, CGT CMC and Analytics, Pharmaron

**Next-Generation Promoters for Retinal Gene Therapy: Unlocking Treatment at Advanced Disease Stages**

[Raghavi Sudharsan](#), Ph.D., Research Assistant Professor, Experimental Ophthalmology, Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania

## CellPort Software Lunch Session

Malvern Room

**Session Host:**

11:45 a.m.-12:45 p.m.

[Shuo Huang](#), Ph.D., Study Director and BD Representative at TriApex

**From Bench to Batch: Operational Readiness for ATMPs in the New Regulatory Era**

[Patrick Dentinger](#), B.S., CEO, CellPort Software

## Company Showcases

Centennial Ballroom II

**Session Chair:**

2:00-2:30 p.m.

[Huize Yan](#), M.S., Sr. Process Development Scientist, Genentech Inc

**Allogeneic iPSC-derived Cell Therapies for Global CNS Disease Patients**

[Karl Johe](#), Ph.D., CSO, Hopstem Biotechnology

2:30-3:00 p.m.

**QIAGEN: A Global Partner for Sample to Insight Solutions**

[Samuel Rulli](#), Ph.D., Director, Product Management, QIAGEN

3:00-3:30 p.m.

**From months to days: Finally, Low-Variability Quantification of Titer, VCN, and Genome Integrity without Tradeoffs.**

[Eleen Shum](#), Ph.D., VP, Product, Countable Labs

# Parallel Sessions I II & III

Friday June 27<sup>th</sup> – CMC

CMC

Grand Ballroom

## Session 1: Trace it back to the Source: Innovations in Plasmid Development

**Session Chair:** [Tim Zhou](#), Ph.D., Purification Process Development Lead, Genentech Inc.  
**10:00-10:30 a.m.** **Challenges and Opportunities in Vector Engineering for Gene Therapies**  
[Daniel Cohen](#), Ph.D., Sr. Director of Vector Engineering Genomics and Computational Biology, Roche  
**10:30-11:00 a.m.** **AAVone: One Plasmid AAV Production System to Revive AAV Gene Therapy**  
[Daozhan Yu](#), Ph.D., CEO, AAVnerGene

CMC

Grand Ballroom

## Session 2: Manufacturing Process Development: Challenges and Breakthroughs

**Session Chair:** [Tim Zhou](#), Ph.D., Purification Process Development Lead, Genentech Inc.  
**2:00-2:30 p.m.** **Single Pass Tangential Flow Filtration (SPTFF) for Continuous and Intensified Processing of AAV**  
[Andrew Zydney](#), Ph.D., Bayard D. Kunkle Chair & Professor of Chemical Engineering, Penn State University  
**2:30-3:00 p.m.** **Gene Therapy Manufacture Using Functionalized nanoDNA Expression Platform**  
[Stephen Hughes](#), Ph.D., CTO, Integrated Biorefining Corporation

CMC

Grand Ballroom

## Session 3: Quality Control: from Analytics to Regulatory

**Session Chair:** [Huize Yan](#), M.S., Sr. Process Development Scientist, Genentech Inc.  
**3:50-4:20 p.m.** **Advance Analytics for Viral Vectors**  
[Lake Paul](#), Ph.D., CEO, BioAnalysis LLC  
**4:20-4:50 p.m.** **Innovating within Control: A CMC Strategy for Regulatory Readiness**  
[Gaurav Chauhan](#), M.S., Founder & Principal Consultant, Chauhan BioConsulting

# Parallel Sessions II & III

Friday June 27<sup>th</sup> – Gene Therapy

## Gene Therapy

Centennial Ballroom I

### Session 1: Paving the Way for Transformative Therapies

**Session Chair:** [Yixuan Ming](#), Ph.D., Process Development Scientist, Genentech Inc.

10:00-10:30 a.m.

**How the Right Models and Tools can Accelerate the Development and Approval of the Therapies**

10:30-11:00 a.m.

[Jenny A. Greig](#), Ph.D., SVP & Head of Operations, Franklin BioLabs

**Academic based Gene Therapy Manufacturing in a Changing Landscape**

[Johannes Van Der Loo](#), Ph.D., Director of Clinical Vector Core, Pathology & Laboratory Medicine, Children's Hospital of Philadelphia

11:00-11:30 a.m.

**Optimizing Delivery of Brain-Delivered Gene Therapy**

[Liz Ramsburg](#), Ph.D., Head of Gene Therapy Research, Roche Innovation Center Philadelphia

## Gene Therapy

Centennial Ballroom I

### Session 2: Novel Targets and Emerging Indications in Gene Therapy

**Session Chair:** [Jingwen Niu](#), Ph.D., Principal Scientist, AlphaThera

2:00-2:30 p.m.

**Unlocking the Full Potential of RNAi for Obesity and Complement-Mediated Diseases**

2:30-3:00 p.m.

[Marc Abrams](#), Ph.D, CTO & Head of US Operations, SanegeneBio,

**Constructing Preformed Guidance Pathways to Target Axonal Growth from Neural Transplants**

[George M. Smith](#), Ph.D., Professor, Depart. of Neural Sciences, Temple University

## Gene Therapy

Centennial Ballroom I

### Session 3: Unlocking Gene Therapy Potential: Scientific Advances and Tools

**Session Chair:** [Namila](#), Ph.D., Process Development Scientist, Genentech Inc.

3:50-4:20 p.m.

**Engineering Delivery Solutions to Unlock Genetic Medicines**

4:20-4:50 p.m.

[Yuan Yuan](#), Ph.D., Associate Scientific Director, Biogen

**Developing Next-Generation AAV Capsids for Intravitreal Gene Therapy Using the Machine Learning-Guided scAAVengr-HUnT Platform**

4:50-5:20 p.m.

[Laura Campello](#), Director of Retinal Gene Therapy, Avista Therapeutics

**Clinical Dosing Strategies for Ocular AAV Gene Therapy**

[Prathap Nagaraja Shastri](#), Ph.D., Scientific Director, Clinical Pharmacology and Pharmacometrics, Johnson & Johnson

# Parallel Sessions II & III

## Friday June 27<sup>th</sup> – Business Track 1

### Business Track 1

Centennial Ballroom II

#### Session 1: Tri-State Bio-Economy: What Makes Our Region Stand Out

**Session Moderator:** [Bryan Tsao](#), Ph.D., Manager, The Chamber of Commerce for Greater Philadelphia

10:00-11:30 a.m.

#### Panelists

[John Coelho](#), B.D.S., Sr. Advisor, NJEDA

[Michelle Cully](#), Ph.D., Life Sciences Economic Development Specialist, Dept. of Community and Economic Development, Commonwealth of Pennsylvania

[Claire Marrazzo Greenwood](#), MS, Executive Director, CEO Council for Growth and SVP, Economic Competitiveness, The Chamber of Commerce for Greater Philadelphia

[Noah Olsen](#), MBA, Director, Innovation, Delaware Prosperity Partnership

### Business Track 1

Haverford Room

#### Session 2: Expanding Philly's Talent Pipeline for Life Sciences

**Session Moderator:** [Maurie Smith](#), Master in City & Regional Planning, Managing Director, Keystone LifeSci Collaborative

2:00-3:30 p.m.

#### Panelists:

[Brianna Butts](#), BS, Aseptic Technician I, Iovance Biotherapeutics

[Mary Carty](#), Ph.D., Director, Education Innovation and Strategic Partnerships, Drexel University

[Kelly Zaccheo](#), Ph.D., Manager, Market & Product Development, Rockland Immunochemicals

### Business Track 1

Centennial Ballroom II

#### Session 3: Sound Policy: Charting a Course Through Turbulent Waters

**Session Moderator:** [Rick Jones](#), MD, MBA, Advisory Partner, BioAdvance Capital

3:50-5:20 p.m.

#### Panelists:

[Lara Flynn](#), BA, Sr. Director, Federal Policy and Public Affairs, LSPA

[Jen Gilburg](#), Master in Management, Deputy Secretary, Technology and Entrepreneurship, Dept. of Community and Economic Development, Commonwealth of Pennsylvania

[Rebecca Grant](#), DVM, Sr Director, Life Sciences & Innovation, Commerce Dept., City of Philadelphia

# Parallel Sessions II & III

## Friday June 27<sup>th</sup> – Business Track 2

### Business Track 2

Centennial Ballroom III

#### Session 1: Money in the Bank: Structuring Your Initial Funding to Attract Further Capital

**Session Moderator:** Jing Yang, Ph.D., Founder & CSO, BaseCure Therapeutics

10:00-11:30 a.m.

**Panelists:**

Glen Gaddy, Ph.D., Managing Member, Robin Hood Ventures  
Rebecca Guzman, JD, Partner & Co-Chair, M&A Division, Duane Morris  
Vatsala Naageshwaran, Ph.D., CEO, Franklin BioLabs  
Pan Pan, Ph.D., M.B.A, SVP, Business Development, OncoC4

### Business Track 2

Centennial Ballroom III

#### Session 2: Women in business: the Philly Story

**Session Moderator:** Sima Kulkardi, JD, MS, BS, Special Counsel: Life Sciences & Intellectual Property, Duane Morris

2:00-3:30 p.m.

**Panelists:**

Lisa Baskin, BS, Sr VP, Scheer Partners  
Melina Blee, Ph.D., Site Head, BioLabs for Advanced Therapeutics Philadelphia  
Audrey Greenberg, MBA, C.P.A., Mayo Venture Partner, Mayo Clinic  
Heather Ross, Ph.D., JD, VP, Technology Licensing & Startups, Thomas Jefferson University and Jefferson Health  
Dongmei Wang, Ph.D., MS, EVP, Global Sales & Marketing and Project Management, Frontage Laboratories  
Amy Williams, BS, President, SageWorksRx

### Business Track 2

Centennial Ballroom III

#### Session 3: How Incubators Reshape the Bio-ecosystem

**Session Moderator:** Melina Blee, Ph.D., Site Head, BioLabs for Advanced Therapeutics Philadelphia

3:50-5:20 p.m.

**Panelists:**

Matthew Burkhardt, BA, Director, B+labs  
Ashley Fuller, Ph.D., CSO, SyzOnc  
Lorenzo Pellegrini, Ph.D., MBA, Managing Partner, Hatch Biofund  
Justin Will, JD, Managing Director, Business Outcomes Managed Services, PwC

# Parallel Sessions IV V & VI

Saturday June 28<sup>th</sup> – Cell Therapy

## Cell Therapy

Grand Ballroom

### Session 1: Recent Advances in Cell Therapy

**Session chair:** [Dharmesh Patel](#), Ph.D., M.B.A, Founder & CEO, Nexis BioConsult

10:10-10:40 a.m.

**Cell Therapy: Past, Present, and Future**

[Michael Kalos](#), Ph.D., Managing Director, Next Pillar Consulting, LLC

10:40-11:10 a.m.

**Engineering CRISPR Systems for Precision Therapeutics and Molecular Innovation**

[Xue \(Sherry\) Gao](#), Ph.D., Presidential Penn Compact Associate Professor, University of Pennsylvania

11:10-11:40 a.m.

**Targeted RNA Therapy for In vivo Cell Engineering**

[Hamideh Parhiz](#), Ph.D., Pharma.D., Assistant Professor, University of Pennsylvania

## Cell Therapy

Grand Ballroom

### Session 2: Optimization of CAR-T Cell Development and Safety Detection

**Session chair:** [Naman Patel](#), M.S., Senior Scientist at Johnson & Johnson Innovative Medicine

1:00-1:30 p.m.

**Developing CAR T Cells with Enhanced Signaling Properties**

[Maria Caterina Rotiroti](#), Ph.D., Research Fellow in Pediatrics, Dana-Farber Cancer Institute, Harvard University

1:30-2:00 p.m.

**Precision Biomaterials Sustain Durable and Massive Expansion of human CAR-T cells in vitro**

[Xiao Huang](#), Ph.D., Assistant Professor, Drexel University

2:00-2:30 p.m.

**Current Standards and Future Directions for off-target CRISPR Endonuclease Detection**

[Robert Cail](#), Ph.D., Postdoctoral Scholar, Johnson & Johnson Innovative Medicine

# Parallel Sessions IV V & VI

Saturday June 28<sup>th</sup> – RNA Therapy

## RNA Therapy

Centennial Ballroom I

### Session 1: Clinical Translation of Nucleic Acid-based Therapy

- Session chair:** [Tao Niu](#), Ph.D., Director, Quantitative Clinical Pharmacology, Sarepta Therapeutics
- 10:10-10:40 a.m.** **Application of Model Informed Drug Developed in Clinical Pharmacology for Oligonucleotides**  
[Xiao Shelley Hu](#), Ph.D., President and Founder, Translational Consulting L.L.C.
- 10:40-11:10 a.m.** **Transform DMD Treatment Through Base Editing Technology**  
[Chunyan He](#), Ph.D., Founder and CEO, GenAssist Ltd
- 11:10-11:40 a.m.** **Solving Analytical Challenges in Oligonucleotide Therapeutics: Insights and Case Studies**  
[Aihua Liu](#), Ph.D., Executive Director, Bioanalysis, Resolian

## RNA Therapy

Centennial Ballroom I

### Session 2: Latest Advances in Nucleic Acid Delivery

- Session chair:** [Huize Yan](#), M.S., Sr. Process Development Scientist, Genentech Inc.
- 1:00-1:30 p.m.** **Revolutionizing LNP Technology for Delivering RNA Medicine: From Discovery to GMP**  
[Zhenghong Gao](#), Ph.D., CTO, XGen Bio
- 1:30-2:00 p.m.** **NamiRNA-Enhancer Network as Novel Target for Developing Small Nuclear Acid Therapy**  
[Wenqiang Yu](#), Ph.D. M.D., Professor in Institute of Biomedical Sciences, Fudan University

# Parallel Sessions IV V & VI

Saturday June 28<sup>th</sup> – Clinical & Regulatory

## Clinical & Regulatory

Centennial Ballroom III

### Session 1: Latest Regulatory Considerations for Gene Therapy

**Session chair:** [Yixuan Ming](#), Ph.D., Process Development Scientist, Genentech Inc.

**10:10-10:40 a.m.** **Regulatory Considerations for Early Clinical Trials for Advanced Therapies**

[Kevin Hennegan](#), MA, SVP, Head of Advanced Therapies, Quantum Regulatory Solutions

**10:40-11:10 a.m.** **Regulatory Trends in Gene Therapy**

[Melody Dai](#), Ph.D., P.M.P., RAC, Founder & CEO, Global Molecular Solutions

## Clinical & Regulatory

Centennial Ballroom III

### Session 2: Early Clinical Development Challenges of Gene and Cell Therapy

**Session chair:** [Melody Dai](#), Ph.D., P.M.P., RAC, Founder & CEO, Global Molecular Solutions

**1:00-1:30 p.m.** **Advancing First-in-Patient Gene Therapy to Treat Glaucoma**

[Bo Liang](#), Ph.D., Founder & CEO, IVIEW Therapeutics Inc.

**1:30-2:00 p.m.** **Clinical Pharmacology Considerations in the Development of Allogeneic Cell Therapies – Opportunities & Challenges**

[Hardik Mody](#), Ph.D., Principal Scientist, Clinical Pharmacology, Genentech

**2:00-2:30 p.m.** **Translational Evidence of CNTY101, an iPSC-derived CD19 Targeting Allogeneic CAR-NK Product in B Cell-driven Autoimmune Diseases**

[Hongxia Zhang](#), Director, Translational Development, Century Therapeutics

# Parallel Sessions IV V & VI

Saturday June 28<sup>th</sup> – Business Track 3 & 4

## Business Track 3

Centennial Ballroom II

### Session 1: Honorable Exit: MNC and IPO

**Session Moderator:** Fang Shen, Ph.D., VP Biology, QuantX Biosciences

10:10-11:40 a.m.

**Panelists:**

Seamus Jiang, M.B.A., Managing Director, PwC  
Andrew Meadow, M.B.A., Founding Partner & CIO, Health Innovation Capital  
Wendy Pan, Ph.D., J.D., Partner & Head of Life Sciences in Asia, Goodwin  
Fay Xing, M.D., M.B.A., Partner, Panacea Venture

## Business Track 3

Centennial Ballroom II

### Session 2: Going Global: Asset Assessment and Strategic Positioning for Deals

**Session Moderator:** Haichen Yang, M.D., M.B.A, M.A., Conference Advisory Committee Co-chair, VP, Clinical Research, Amicus Therapeutics

1:00-2:30 p.m.

**Panelists:**

Marian Nakada, Ph.D., VP, Venture Investments, JJDC  
Difei Yang, Ph.D., MBA, COO&CFO, Kanglin Bio  
Zhen Yang, Ph.D., Sr. Director, Global Business Development & Alliance Management, Hansoh Pharma

## Business Track 3

Centennial Ballroom II

### Session 3: AI Impact: Harnessing the Coming Tsunami

**Session Moderator:** Michelle Lu, BA, Director of Product, OncoLens

2:50-4:20 p.m.

**Panelists:**

Dimitris K Agrafiotis, Ph.D., Director, Digital, Analytics, and AI, Arsenal Capital Partners  
Gregory Jackson, Ph.D., EVP, Life Sciences Greenhouse Investments  
Aaron Mackey, Ph.D., SVP, AI & Development, Lokavant  
Irene Rombel, Ph.D., MBA, CEO & Co-Founder, BioCurie

## Business Track 4

Centennial Ballroom III

### Session 1: Realizing Potential: New Drug Commercialization

**Session Moderator:** Sunil Joshi, MBA, MS, President & CEO, Protelis Biotechnology

2:50-4:20 p.m.

**Panelists:**

Jeff He, MBA, MA, Sr Director, Global Marketing, Genmab  
Man Guo, MS, Sr Director, Commercial Insights and Analytics, Bayer  
Laurent Metz, MD, MBA, Partner, Robin Hood Ventures  
Paul Zhang, MBA, MS, Partner, Bluestar BioAdvisors

## Keynote Speakers



**Phyllis Arthur, M.B.A.**  
*EVP & Head, Healthcare Policy and Programs*  
Biotechnology Innovation Organization (BIO)

Phyllis Arthur is the Executive Vice President & Head of Healthcare Policy and Programs at the Biotechnology Innovation Organization (BIO). In this role Ms. Arthur is responsible for leading on a robust portfolio of healthcare policy issues with member companies, including on pricing, reimbursement, and access, infectious disease, national security, and capital formation. Previously she served as the SVP for Infectious Disease and Emerging Science Policy, working with member companies in vaccines, antimicrobial resistance and biodefense on policy, legislative and regulatory issues. Ms. Arthur joined BIO in July 2009 as the Director of Healthcare Regulatory Affairs.

Prior to joining BIO, she worked in numerous marketing and sales positions for Merck & Co Inc in their Vaccine Division. Over her 16-year career at Merck, Ms. Arthur launched several exciting new vaccines in the United States and internationally, including the first HPV vaccine, GARDASIL. During her years in Marketing, she worked closely with clinical and academic thought leaders in infectious diseases, oncology and public health. In addition, Ms. Arthur also led a large vaccine sales organization of over 75 representatives and managers covering 14 states.

Before graduate school, Ms. Arthur worked as a research assistant for two economists at the Brookings Institution in Washington, DC. There she conducted economic analyses related to savings and investment policies for the OECD countries.

Ms. Arthur received her B.A. in 1987 in Economics and International Politics from Goucher College and her M.B.A. in 1991 from the Wharton School of Business at the University of Pennsylvania.



**James L. Riley, Ph.D.**  
*Professor of Microbiology*  
University of Pennsylvania

James Riley received his graduate degree in Genetics and Molecular Biology from Emory University. Dr. Riley's lab studies the signals that control primary human T cell activation and function with special attention to how these manipulations can

be exploited to develop T cell therapies for HIV, autoimmune disease and cancer. We are studying how to best re-direct and expand human T regulatory cells for use in the treatment of autoimmune disease. We are evaluating both the use of TCR and CARs to redirect Tregs and studying both how these methods provide antigen suppression and if these approaches alter T regulatory cell stability. Part of this research is studies to understand how altering the media by which T cells are expanded in alters their function and engraftment potential in vivo. These studies have spurred interested on how various metabolic pathways are perturbed by external signaling and environment. The lab is also focused on designing HIV resistant, HIV specific T cells to be key players in the HIV Cure effort. As a leader of the BEAT HIV Martin Delaney Collaboratory his lab is evaluating ways to make T cells resistant to HIV entry and integration and developing HIV-1 specific chimeric antigen receptors to evaluate the ability of these T cells to control HIV replication in both in vitro and humanized mouse studies. Dr. Riley's basic research findings using primary human T cells have been used as the basis and rationale for numerous Phase I adoptive T cell therapy clinical trials.



**James M. Wilson, Ph.D., M.D.**  
*President, CEO*  
GEMMA Biotherapeutics

Having started his work in gene therapy nearly 40 years ago, Dr. Wilson was recruited to the University of Pennsylvania in 1993 and created the first and largest academic-based program in gene therapy. His laboratory discovered a family of viruses from primates called adeno-associated viruses (AAV) that could be engineered to be very effective gene transfer vehicles. These 'vectors' have become the technology platform of choice and have set the stage for the recent resurgence of the field of gene therapy.

Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of ten biotechnology companies. His research has been focused on rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of neurologic disorders and liver metabolic diseases, and on addressing these unmet needs for patients in marginalized populations. To date, his team's accomplishments include 3 FDA-approved AAV-based gene therapies, approximately 20 active programs currently in development, 95 patents on gene therapy-related technologies, and first-in-patient studies in 15 different diseases.

# Speakers



**Marc Abrams, Ph.D.**  
*CTO and Head of US Operations*  
SanogeneBio



**Robert Cail, Ph.D.**  
*Postdoctoral Scholar–Genomic Safety*  
Johnson and Johnson



**Dimitris Agrafiotis, Ph.D.**  
*Director, Digital, Analytics and AI*  
Arsenal Capital Partners



**Laura Campello, Ph.D.**  
*Director, Retinal Gene Therapy*  
Avista Therapeutics



**Melina Blee, Ph.D.**  
*Site Head*  
BioLabs for Advanced Therapeutics Philadelphia



**Mary Genevieve Carty, DHSc-c, M.S., MHEd**  
*Director of Education Innovation and Strategic Partnerships, Department of Microbiology and Immunology*  
Drexel University College of Medicine



**Matthew Burkhardt, B.A.**  
*Director*  
B+labs



**Gaurav Chauhan, M.S.**  
*Founder, President*  
Chauhan BioConsulting



**Brianna Shantay Butts, B.S.**  
*Aseptic manufacturing technician II/ Manufacturing*  
Iovance



**John F Coelho, B.D.S**  
*Senior Advisor, Life Sciences and Healthcare*  
New Jersey Economic Development Authority (NJEDA)



**Daniel M Cohen, Ph.D.**  
*Sr. Director, Vector Engineering  
 Genomics and Computational  
 Biology*  
 Roche



**Ashley M Fuller, Ph.D.**  
*Co-founder — Chief Scientific  
 Officer*  
 SyzOnc



**Michelle Cully, Ph.D.**  
*Life Sciences Economic Specialist*  
 Pennsylvania Department of  
 Community and Economic  
 Development



**Glen Gaddy, Ph.D.**  
*Managing Member*  
 Robin Hood Ventures



**Melody Dai, Ph.D., P.M.P.**  
*Founder & CEO*  
 Global Molecular Solutions



**Xue Gao, Ph.D.**  
*Presidential Penn Compact Asso-  
 ciate Professor*  
 University of Pennsylvania



**Patrick Dentinger**  
*CEO*  
 CellPort Software



**Zhenghong Gao, Ph.D.**  
*CTO*  
 XGen Bio



**Lara Flynn**  
*Senior Director, Federal Policy &  
 Public Affairs*  
 Life Sciences PA



**Jen Gilburg**  
*Department of Community &  
 Economic Development, Deputy  
 Secretary of Technology and En-  
 trepreneurship*  
 Commonwealth of Pennsylvania



**Rebecca L. Grant, DVM**  
*Senior Director, Life Sciences & Innovation*  
 City of Philadelphia (Commerce Dept)



**Rebecca A. Guzman, JD, B.S.**  
*Partner, Co-Chair of M&A Division*  
 Duane Morris LLP



**Audrey E. Greenberg, M.B.A., C.P.A.**  
*Mayo Venture Partner*  
 Mayo Clinic



**Chunyan He, Ph.D.**  
*CEO*  
 GenAssist Ltd



**Claire Greenwood, M.S.**  
*Executive Director and Senior Vice President of Economic Competitiveness*  
 The Chamber of Commerce for Greater Philadelphia



**Jeff He, M.B.A., B.A.**  
*Senior Director, Global Marketing*  
 Genmab



**Jenny A. Greig, Ph.D.**  
*Senior Vice President, Head of Operations*  
 Franklin Biolabs



**Kevin Hennegan, M.A.**  
*Head of Advanced Therapies*  
 Quantum Regulatory Solutions



**Man Guo**  
*Senior Director, Insights & Analytics*  
 Bayer



**Xiao Shelley Hu, Ph.D.**  
*President and Founder*  
 Translational Consulting L.L.C.



**Kevin Huang**  
*Co-founder & CEO*  
 Hope for Rare Foundation



**Seamus Jiang, M.B.A**  
*Managing Director, Deals*  
 PwC



**Xiao Huang, Ph.D.**  
*Assistant Professor, School of  
 Biomedical Engineering*  
 Drexel University



**Karl K Johe, Ph.D.**  
 CSO  
 Hopstem Biotechnology



**Stephen Hughes, Ph.D.**  
 CTO  
 Integrated Biorefining Corpora-  
 tion



**Rick Jones**  
*Advisory Partner*  
 BioAdvance Capital



**Gregory Jackson, Ph.D.**  
*Executive Vice President*  
 Life Sciences Greenhouse Invest-  
 ments



**Sunil Joshi, M.B.A, M.S.**  
*President & CEO*  
 Protelis Biotechnology



**Vibha Jawa, Ph.D., FAAPS**  
*Chief Scientific Officer*  
 EpiVax, Inc.



**Sima Singadia Kulkarni, JD,  
 M.S., B.S.**  
*Special Counsel: Life Sciences &  
 Intellectual Property*  
 Duane Morris



**Bo Liang, Ph.D.**  
*CEO*  
 IVIEW Therapeutics Inc.



**Laurent D Metz, M.D.,  
 M.B.A, M.S.**  
*Partner*  
 Robin Hood Venture



**Aihua Liu, Ph.D.**  
*Executive Director, Bioanalysis*  
 Resolian (Formally Alliance  
 Pharma)



**Hardik Mody, Ph.D.**  
*Principal Scientist, Clinical  
 Pharmacology*  
 Genentech



**Michelle Lu, B.A.**  
*Director of Product*  
 OncoLens



**Vatsala Naageshwaran, Ph.D.,  
 M.S.**  
*CEO*  
 Franklin BioLabs



**Aaron Mackey, Ph.D.**  
*SVP AI & Development*  
 Lokavant, Inc.



**Prathap Nagaraja Shastri,  
 Ph.D.**  
*Scientific Director, Clinical Phar-  
 macology and Pharmacometrics*  
 Johnson and Johnson



**Andrew Marc Meadow,  
 M.B.A**  
*Partner, Chief Investment Officer*  
 Health Innovation Capital



**Marian Nakada, Ph.D.**  
*VP Venture Investments, JJDC*  
 Johnson & Johnson



**Noah Olson, M.B.A**  
*Director of Innovation*  
 Delaware Prosperity Partnership



**Naman K Patel, M.S.**  
*Senior Scientist, Discovery*  
*Technology & Molecular Pharmacology*  
 Johnson & Johnson Innovative Medicine



**Pan Pan, Ph.D., M.B.A**  
*SVP, Business Development*  
 OncoC4 Inc



**Lake Paul, Ph.D.**  
 CEO  
 BioAnalysis



**Wendy Pan, Ph.D., JD**  
*Partner & Head of Life Sciences*  
*in Asia*  
 Goodwin



**Lorenzo Pellegrini, Ph.D., M.B.A**  
*Managing Partner*  
 Hatch Biofund



**Hamideh Parhiz, Ph.D., Pharma.D.**  
*Assistant Professor of Pharmacology/Department of Pharmacology*  
 University of Pennsylvania



**Silvia Pires Lourenco, Ph.D., M.S.**  
*Director, CGT CMC and Analytics*  
 Pharmaron



**Dharmeshkumar Patel, Ph.D., M.B.A**  
*Founder and CEO*  
 Nexis BioConsult



**Amanda Purdy, Ph.D.**  
*Associate Chief Academic Officer*  
 Fox Chase Cancer Center



**Liz Ramsburg, Ph.D.**  
*Head of Gene Therapy Research*  
 Roche Innovation Center  
 Philadelphia



**Fang Shen, Ph.D.**  
*VP*  
 QuantX Bio



**Irene Rombel, Ph.D., M.B.A.**  
*CEO, President and Co-Founder*  
 BioCurie



**Eleen Shum, Ph.D.**  
*VP of Product*  
 Countable Labs



**Heather Rose, Ph.D., JD**  
*Vice President, Technology Licens-  
 ing & Startups*  
 Thomas Jefferson University and  
 Jefferson Health



**George M Smith, Ph.D.**  
*Professor, Department of Neural  
 Sciences*  
 Temple University



**Maria Caterina Rotiroti,  
 Ph.D.**  
*Research Fellow, Pediatrics*  
 Dana-Farber Cancer Institute



**Maurie Smith**  
*Managing Director*  
 Keystone LifeSci Collaborative



**Samuel Rulli, Ph.D.**  
*Director Product Management*  
 QIAGEN



**Raghavi Sudharsan, Ph.D.**  
*Research Assistant Professor of  
 Experimental Ophthalmology,  
 Department of Clinical Sciences  
 & Advanced Medicine*  
 University of Pennsylvania



**Bryan Tsao, Ph.D., B.S.**  
*Manager*  
 The Chamber of Commerce for  
 Greater Philadelphia



**Fay Xing, M.D., M.B.A**  
*Partner*  
 Panacea Venture



**Patricia Tsao, Ph.D., M.D.**  
*Chief Operating Officer and  
 Scientific Director*  
 CytoEX Inc.



**Difei Yang, Ph.D., M.B.A**  
*COO & CFO*  
 Kanglin Bio



**Dongmei Wang, Ph.D.**  
*EVP*  
 Frontage



**Haichen Yang, M.D., M.B.A,  
 M.A.**  
*Vice President, Clinical Research*  
 Amicus Therapeutics



**Justin Will, JD, B.S.**  
*Managing Director, Business  
 Outcomes Managed Services*  
 PwC



**Jing Yang, Ph.D.**  
*Founder, Acting Chief Executive  
 Officer and Chief Scientific Offi-  
 cer*  
 BaseCure Therapeutics



**Amy Williams**  
*President*  
 SageWorks Rx



**Zhen Yang, Ph.D.**  
*Senior Director, Global Business  
 Development & Alliance Man-  
 agement*  
 Hansoh Pharma



**Daozhan Yu, Ph.D.**  
*CEO*  
 AAVnerGene Inc.



**Hongxia Zhang, Ph.D.**  
*Director, Translational Development, EDT*  
 Century Therapeutics



**Wenqiang Yu, Ph.D., M.D.**  
*Professor in Institutes of Biomedical science*  
 Fudan University



**Paul Zhang, M.B.A**  
*Partner*  
 Bluestar BioAdvisors, LLC



**Yang Yuan, Ph.D., M.B.A**  
*Associate Director*  
 Jazz Pharmaceuticals



**Andrew Zydny, Ph.D.**  
*Bayard D. Kunkle Chair and Professor of Chemical Engineering*  
 Penn State University



**Yuan Yuan, Ph.D.**  
*Associate Scientific Director*  
 Biogen



**Michael Kalos, Ph.D.**  
*Managing Director*  
 Next Pillar Consulting



**Kelly Zaccheo, Ph.D.**  
*Manager, Market and Product Development in Special Projects*  
 Rockland Immunochemicals



**Johannes van der Loo, Ph.D.**  
*Director Clinical Vector Core, Pathology and Laboratory Medicine*  
 Children's Hospital of Philadelphia

## Advisory Chairs



Haichen Yang, M.D., M.B.A.,  
M.A.  
*Vice President, Clinical Research*  
Amicus Therapeutics



Jing Yang, Ph.D.  
*Founder, Acting Chief Executive  
Officer and Chief Scientific Officer*  
BaseCure Therapeutics

## Advisory Committee



Jim Fendrick  
*President and CEO*  
Rockland Immunochemicals



Audrey E Greenberg, M.B.A.,  
C.P.A.  
*Mayo Venture Partner*  
Mayo Clinic



Guangping Gao, Ph.D.  
*Professor*  
UMASS Chan Medical School



Federico Mingozi, Ph.D.,  
MBA  
*CEO*  
Newco

# Leadership Team



Lu Wang, Ph.D., M.B.A.  
*Director, Process Development*  
Genentech



Jin Wen, Ph.D.  
*Sr. Scientist, Analytical Development*  
Genentech



Xinjun Zhang, Ph.D.  
*Associate Principal Scientist/Associate Director*  
Merck



CJ (Chunjuan) Song, Ph.D.  
*VP R&D*  
Exegensis Bio



Yufeng Li, Ph.D.  
*2024-25 President*  
SAPA-GP



Huize Yan, M.S.  
*Senior Scientist*  
Genentech



Tao Niu, Ph.D.  
*Director, Quantitative Clinical Pharmacology*  
Sarepta Therapeutics

# Organizing Committee



**Namila, Ph.D.**  
*Scientist, Purification Process  
Development*  
Genentech



**Yifan Gong, Ph.D.**  
*Senior Scientist, DMPK*  
Frontage Laboratory



**Lisa Baskin**  
*Sr Vice President*  
Scheer Partners



**Shuo Huang, Ph.D.**  
*Study Director/BD Representa-  
tive*  
TriApex



**Zhiyi Cui, Ph.D.**  
*Associate Director, DMPK*  
GSK



**Chao Li, M.D., M.S.**  
*Lab manager, Medicine*  
University of Pennsylvania



**Jake Dong, Ph.D.**  
*Sr. SCIENTIST*  
FRONTAGE



**Bill Lu, M.B.A**  
*Principal*  
Forerun Advantage



**Shuai Dong, Ph.D.**  
*Senior Manager, Quantitative  
Clinical Pharmacology*  
Sarepta Therapeutics



**Jialie Luo, Ph.D.**  
*Data Scientist*  
Cencora PharmaLex



**Yixuan Ming, Ph.D.**  
*Scientist, Purification Process  
 Development*  
 Genentech



**Saisi Xue, Ph.D.**  
*Principal Scientist*  
 BMS



**Hao Sun, M.S.**  
*Senior Scientist*  
 Merck & Co.



**Zhongyue (Claire) Yuan,  
 M.S.**  
*Graduate Student Industrial  
 and Molecular Pharmaceutics*  
 Purdue University



**Hui Wang, Ph.D.**  
*Head of US Business Develop-  
 ment*  
 Genevovager



**Xinjun Zhang, Ph.D.**  
*Associate Principal Scien-  
 tist/Associate Director*  
 Merck



**Ruixi Wang, Ph.D.**  
*Scientist, Purification Process  
 Development*  
 Genentech



**Ronghui Zhou, Ph.D.**  
*IT Lead*  
 SAPA-GP



**Sherry Wang, M.S.**  
*Logistics/Operation Lead*  
 SAPA-GP



**Tim Zhou, Ph.D.**  
*Lead Scientist, Purification Pro-  
 cess Development*  
 Genentech

# Organizing Committee

## Leadership Team

**Conference Chair**  
**Conference Co-Chair**  
**Program Director**  
**Program Co-Director**

Lu Wang  
Xinjun Zhang, Yufeng Li  
Jin Wen, Tao Niu  
Chunjuan (CJ) Song, Huize Yan

## Advisory Chair

Haichen Yang

Jing Yang

## Advisor

Audrey Greenburg

Federico Mingozzi

Guangping Gao

Jim Fendrick

**Operating Committee**  
**Marketing/Communication**  
**Project Management**  
**IT/Website**  
**Logistics**  
**Business Development**  
**Partnership**

**Track Leads**  
**Gene Therapy**  
**Cell Therapy**  
**CMC**  
**Clinical & Regulatory**  
**RNA Therapy**  
**Business**  
**Lunch Session and Company Showcase**

## Name

Namila, Zhiyi Cui  
Hao Sun, Shuo Huang, Zhongyue (Claire) Yuan  
Ruixi Wang, Ronghui Zhou, Jialie Luo  
Sherry Wang, Yifan Gong  
Hui Wang  
Bill Lu

## Name

Chunjuan (CJ) Song, Yixuan Ming, Chao Li  
Jake Dong, Shuai Dong  
Tim Zhou  
Tao Niu  
Tao Niu  
Bill Lu, Lisa Berger Baskin  
Hui Wang

# Session Chairs and Volunteers

## Session Chairs and Hosts

Bryan Tsao	Dharmesh Patel	Fang Shen	Haichen Yang	Huize Yan
Jing Yang	Jingwen Niu	Lu Wang	Maurie Smith	Melina Blees
Michelle Lu	Naman Patel	Namila	Patricia Tsao	Rick Jones
Shuo Huang	Sima Kulkardi	Sunil Joshi	Tao Niu	Tim Zhou
Yixuan Ming	Zhiyi Cui			

## Volunteers

Alvin Chen	Bo Yu	Bradley Zhang	Daisy Li	Dan Luo
David Cui	Derui Huang	Dian He	Elsa Bai	Evelyn Guo
Emily Zhang	Fei Meng	Ian Sun	Isabella Xie	James Huang
Jeffrey Wang	Jerry Rao	Jie Cui	Jingwen Niu	Kaifen Wang
Katie Sun	Kairui Wang	Keman Xu	Lele Song	Lily Chen
Mengqi Chai	Minghao Li	Ping Kong	Qingyang Li	Ran Li
Ruijun Zhu	Samuel Wu	Sophia Wu	Sophie Johnson	Taylor Qiu
Tiffany Lu	Victor Chen	Vincent Gao	Vincent Xia	Wenji Lei
Xiaomei Wang	Yanchun Li	Yifeng Chen	Yonghai Li	Yiliu Hu
Ying Liu	Yubo Jin	Zoe Zhang	Ziyu Song	

# Upcoming Event





# Bring your life-saving therapies to market faster, with confidence

Explore our knowledge hub to see how we can advance your cell and gene therapy development.

Here's what you'll find:

- Scalable digital PCR solutions and standardized workflows for:
  - Absolute quantification of AAV genome titers
  - Robust detection of residual host cell DNA contaminants
  - Confirmation of CRISPR-mediated editing events in CAR-T cells
- Grants and partnerships to help grow your business
- Bespoke packages and services to address your company's needs



Visit [www.qiagen.com/pharma-biotech](https://www.qiagen.com/pharma-biotech) or scan the QR code to learn more.



Trademarks: QIAGEN®, Sample to Insight®, (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law. QPRO-3688 05/2023 © 2023 QIAGEN, all rights reserved.



Sample to Insight



Dedicated to developing FIC allogeneic iPSC cell therapy products for global CNS diseases patients.



Global patents in iPSC reprogramming, neural differentiation and cell engineering.



hNPC01, iPSC-derived forebrain neural progenitor cell injection, received FDA IND clearance in 2024. Positive outcome of phase I clinical trial targeting chronic ischemic stroke supports hNPC01 as a RMAT product.

Pipeline	Indication	R&D	CMC	Preclinic	Phase 1	Phase 2/3
hNPC01 Human Forebrain Neural Progenitor Cell	Stroke	[Progress bar: R&D, CMC, Preclinic, Phase 1]				
	Epilepsy	[Progress bar: R&D, CMC, Preclinic]				
	Traumatic Brain Injury	[Progress bar: R&D, CMC]				
	Cerebral Palsy	[Progress bar: R&D]				

Contact Us

BD@hopstem.com

www.hopstem.com



**“From Bench to Batch: Operational Readiness for ATMPs in the New Regulatory Era”**

**Presented by:** Patrick Dentinger, CEO of CellPort

**Location and Time:** June 27, at 11:45AM in the Malvern Room

**In this talk, we will cover:**

- The cost barriers facing ATMP manufacturing and how regulators are signaling openness to new, more flexible approaches
- A practical digitalization strategy to enhance traceability, regulatory compliance, and day-to-day lab efficiency
- The value of contextualized, transparent data capture in enabling both regulatory alignment and scalable operations



Visit our website at [www.cellportsoftware.com](http://www.cellportsoftware.com)

# Integrated Solutions for Cell & Gene Therapy Product Development



Preclinical / <i>in vivo</i>	Bioanalysis	CMC And Analytics
<ul style="list-style-type: none"> <li>Product Type - Cell and gene therapy, LNPs, vaccines, biologics, small molecules</li> <li>Study type - PK, Distribution, Tolerability, Toxicity/Safety</li> <li>Stages - Discovery to IND enabling GLP toxicology studies</li> <li>Species - Mouse, Rat, Dog, Minipig, Rabbit, Sheep, NHP</li> <li>Dose Routes - Standard and specialized (Ocular, CNS, Cardiovascular)</li> <li>Models - Wild-type, Transgenic, Immunocompromised, disease state</li> <li>Facility - AAALAC-accredited, in-house IACUC, USDA registered, FDA inspected/audited, ISO certified</li> </ul>	<ul style="list-style-type: none"> <li>Biodistribution, viral shedding</li> <li>Cell fate, engraftment</li> <li>Biomarkers</li> <li>Immunogenicity (humoral and cellular response)</li> <li>Immunophenotyping</li> <li>Stage of Development                             <ul style="list-style-type: none"> <li>Discovery/Screening</li> <li>Preclinical</li> <li>Clinical</li> <li>Quality</li> </ul> </li> <li>Non-GLP</li> <li>GLP/GCLP</li> <li>CLIA</li> <li>Platforms                             <ul style="list-style-type: none"> <li>qPCR, dPCR, ddPCR, LC-MS/MS, ELISA, MSD, Flow, Luminex, HPLC and more</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Scalable AAV GMP manufacturing platform leveraging suspension and chromatography-based processes, with high-throughput</li> <li>Proprietary cell line and plasmid technology optimized for enhanced production efficiency</li> <li>Comprehensive biophysical and physicochemical characterization package to support regulatory filings</li> <li>Customizable, phase-appropriate potency assay development, validation, and testing</li> <li>Generation &amp; Testing of Master and Working Cell banks</li> <li>Experienced team with end-to-end product development expertise</li> </ul>

pharmaron.com



## Countable Labs.

Don't be limited  
by qPCR and digital PCR.  
Count on Countable PCR.

### JOIN TALK

From months to days: Finally low-variability quantification of titer, VCN, and genome integrity without tradeoffs

June 27 | 3:00-3:30 pm | Centennial Ballroom II

Eleen Shum

Founding Scientist + VP of Product

# Franklin Biolabs

CELL & GENE | RNA | BIOLOGICS

Accelerating  
Advanced Therapies  
from Discovery to Commercialization

## Contract Research Services

Preclinical | Translational

Vector | CMC | Analytics

Bioanalytics

Greater Philadelphia  
franklinbio.com  
info@franklinbio.com  
+1 (484) 455-4011



## AAVnerGene

Together We Find The Cures

At AAVnergene, we are passionate about empowering researchers by providing a comprehensive range of **AAV products** and **AAV services**, including AAV premade products, vector design, packaging service, AAV characterizations, AAV capsid library constructions, and shRNA selection service.



**AAVone**  
An All-in-One  
Plasmid System for  
Efficient AAV  
Production



**ATHENA**  
Platform for AAV  
Capsid Selection,  
Comparison, and  
Evolution

SCAN ME



### Technologies



9620 Medical Center Drive Suite 100 Rockville, MD 20850

Email: [customer@aavnergene.com](mailto:customer@aavnergene.com)

Website: [www.aavnergene.com](http://www.aavnergene.com)

# BIOSYSTEMS Acro


Where Proteins and Innovation  
Advance Biomedicine

## Core Product and Services

Built on Industry-Leading Technology Platforms  
Offering Diverse Product Selections for Customers



## Overcoming Challenges With Innovation From Discovery To The Clinic



Learn more about  
ACROBiosystems at:  
[www.acrobiosystems.com](http://www.acrobiosystems.com)



# BioAnalysis

## Your Partner Through the Pipeline



**White-glove** customer support throughout your analytical journey. Our **GMP-qualified** technologies support **emerging therapies** including HCPs, LNPs, mRNA, Guide RNAs, ADCs, and PROTACS.

### Recent Research Publication

Targeted Protein Degradation: "A paradigm shift: analytical ultracentrifugation as a multi-attribute platform method in targeted protein degradation"

- *European Biophysics Journal* (2025)



Learn More

# 100+

Years Combined  
Experience

# 70+

Peer-Reviewed  
Publications

## BioAnalysis LLC

3401 I Street, Suite 206  
Philadelphia, PA 19134

E [info@bioanalysisllc.com](mailto:info@bioanalysisllc.com)

P (305) 609-5197

W [bioanalysisllc.com](http://bioanalysisllc.com)



## Gene and Cell Therapy Analytical Services

Frontage offers custom development and platform assays, technology transfers, and stability programs.

### Gene Therapy Experience

- Adenovirus (Ad), Adeno-Associated Virus (AAV) and Custom Recombinant Viruses
- Biophysical Characterization (AUC, PTM analysis)
- Cell-Based Assays (TCID50)

### Cell Therapy Experience

- IND-Enabling Analytical Development and Validation Services
- MOA-Driven and Potency Assay
- Molecular, Immunology and Virology Expertise

Scan the QR code for more information on our Gene and Cell Therapy Services



## Your Partner for AAV Gene Therapy

### Accelerate Your Gene Therapy Program from Discovery to the Clinic

- Drug design and optimization
- Efficacy studies *in vitro* and *in vivo*
- Safety evaluation in mice and NHP
- Investigator-initiated trials

### Proprietary Bac/Sf9 AAV Platform

- Rapid, linear scale up from 2L to 500L
- High purity (GOI > 99%), no rcAAV, high infectivity
- Compliant with FDA/EMA standards

### Custom Services

- 20,000+ Packaging, 3,000+ pre-made AAVs
- 50+ Capsids, 150+ promoters, 10,000+ plasmid backbones
- CRISPR, gene editing, gene cloning, and more
- Oncolytic virus, LV, HSV and more

+1 (215) 205-6963

globalbd@genevoyager.com

www.genevoyager.ltd

**Gene Editing Reagents**

GMP-Grade AccuBase™ Base Editor  
 GMP-Grade Cas9 Protein  
 Cas9 ELISA Kit  
 Cas12a Protein  
 GMP-Grade MaxNuclease™  
 AAV Titration ELISA Kits

**Cell Therapy Reagents**

MHC Monomers & Tetramers  
 Peptide-Ready MHCs  
 HLA-G & LILRBs  
 Custom Soluble TCR Expression  
 Laminin 521  
 Cytokines

**mRNA Production Enzymes**

GMP-Grade T7 RNA Polymerase  
 Restriction Endonucleases  
 RNase R  
 RNase H  
 T4 RNA Ligase  
 MDA5 dsRNA Quantification Kit

Unlock your cell and gene therapy potential with quality recombinant proteins, enzymes, and ELISA kits.



cGMP Manufacturing



ISO13485 Certified




FDA Drug Master Files



Activity Testing



3000+ Catalog Products



Optimized Expression Systems

Off-the-shelf products | Next-day shipping

support@kactusbio.us | kactusbio.com

# Biocytogen, Your Partner from Targets to Therapeutics



**Antibody Therapeutics R&D**



**RenMice:** Fully human antibody/TCR platforms



**400k - 500k** Off-the-shelf fully-human antibody sequences



**FIC/BIC PCC stage assets:** mAb, bsAb, bsADC, Hu-VHH, TCRn



**Partnerships**  
 150+ assets licensing agreement  
 50+ target-nominated RenMice® licensing projects



**Preclinical Products & Services**



**Gene editing services:** ESC/HR and EGE™ 4900+ customized projects delivered



**3300+** Off-the-shelf humanized and/or immunodeficient animal & cell models



**Pharmacology services:** One-stop customized project plans



**Partnerships**  
 All of **TOP 10** MNCs are using BioMice

## Analytical workflows for gene editing therapies

- Achieve high-resolution integrity analysis of RNA across a wide size range
- Determine purity of guide RNA and Cas9 mRNA
- Detect RNA samples extracted from LNPs with high sensitivity



## Human Serum for Cell Culture Media

Xeno Free

[www.seruminnovations.com](http://www.seruminnovations.com)

**SERUM**  
INNOVATIONS  
Division of Life Plasma



Normal & Male AB Serum



### Order Online

Place an order at  
[www.seruminnovations.com](http://www.seruminnovations.com)

### Talk to an Expert



+1-508-439-0844



### Worldwide

Free 2-day shipping on all  
orders over \$1,000



[contactus@lifeplasma.com](mailto:contactus@lifeplasma.com)



### Request a Sample

[contactus@lifeplasma.com](mailto:contactus@lifeplasma.com) to  
request a free sample



[www.seruminnovations.com](http://www.seruminnovations.com)




Your Bridge from ATMP Concept to Commercialization

**Want to get in-human data faster and more cost-effectively?  
Learn about Investigator-Initiated Trials (IIT) with us!**

**Your True CGT CDMO Partner**

- CAR-T, NK, iPSC, MSC, HSC manufacturing
- iPSC reprogramming mRNA-LNP kit
- AAV, LVV, RVV, Oncolytic viruses
- Plasmids, mRNA, circRNA, saRNA, & LNP

1 800-663-2528  
contact@ubrigene.com  
www.ubrigene.com




*Space and support designed for top therapeutics startups with an eye on getting to the clinic — fast!*

- FULL SUITE OF PROCESS DEVELOPMENT EQUIPMENT
- ONSITE WORKFLOW-BUILDING EXPERTISE
- FLEXIBLE SPACE + SUPPORT SERVICES
- COWORKING, PRIVATE LABS, & GRADUATE SUITES IN THE HEART OF PHILADELPHIA



JOIN US NOW FOR  
HARD-HAT TOURS

**biolabs** for **ADVANCED THERAPEUTICS**  
philadelphia



This is where transformations happen.



At Bristol Myers Squibb, the work you do will help people prevail over serious diseases. This isn't easy work, but it is uniquely interesting. This is where you will rewrite the rules, solve the toughest challenges, and create miracles.

It may just transform your career.



Join our talent community!

Scan QR code and click Register.

Learn more at [careers.bms.com](https://careers.bms.com)

©2025 Bristol-Myers Squibb Company. All rights reserved. Bristol-Myers Squibb Company is an Equal Opportunity Employer.



**T Cell Isolation, Redefined.** Scalable. Cost-Efficient. GMP-Ready.

*Akadeum's microbubble kits deliver consistent, high-purity T cell isolation in under an hour. No magnets, no columns, no specialized equipment. Compatible with closed-system, in-bag processing or integration into existing instrumentation, our kits support decentralized manufacturing and streamline clinical progress.*

LOWER COSTS



**Less Time → Faster Clinical Progress**  
Isolate or deplete T cells in under an hour.

**Smaller Footprint → Scalable and Flexible**  
Process >50 billion cells without specialized lab equipment.

DECENTRALIZED




**Anywhere → Universal Compatibility**  
Compatible with any standard lab setup.

BETTER THERAPIES



**Healthier Cells → Enhanced Outcomes**  
Over 20% more viable cells.

**More Cells → More Doses**  
Recover up to 9 times more cells.



[akadeum.com](https://akadeum.com)



Gain insights from drug discovery to commercialization.



**Together, let's break through.**

Get started at [labcorp.com/biopharma/breakthrough](https://labcorp.com/biopharma/breakthrough)



©2024 Labcorp. All rights reserved.



---

*See You  
Next Year!*

---



**2026 @Phily Cell and Gene Therapy Conference May 8<sup>th</sup> – 9<sup>th</sup>, 2026**



---

*See You  
Next Year!*

---

